Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 13daratumumab 7Bortezomib 7Cyclophosphamide 6Calcium Dobesilate 5ixazomib 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4venetoclax 3belantamab mafodotin 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3pomalidomide 2isatuximab 2X-Rays 2Polymerase Chain Reaction 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Biopsy 2siltuximab 1Valganciclovir 1Tissue Banks 1Therapeutics 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Focal Adhesion Protein-Tyrosine Kinases × 1 year × Clear all
NCT07079423 2025-07-23

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡